ameera-3: amcenestrant does not improve pfs in er /her2- breast cancer
Published 2 years ago • 68 plays • Length 2:46Download video MP4
Download video MP3
Similar videos
-
1:51
ameera-3: serd for er her2- breast cancer
-
1:25
ameera-5: amcenestrant palbociclib for previously untreated er /her2- advanced breast cancer
-
0:52
patient eligibility in the ameera-6 trial of amcenestrant
-
4:40
ameera-1 updates: amcenestrant plus palbociclib for patients with er /her2– advanced breast cancer
-
2:35
ameera-6: amcenestrant, a novel serd, in hr breast cancer
-
2:35
what does the future hold for serds in er breast cancer?
-
1:27
emerald: elacestrant vs physicians choice in er /her2- breast cancer
-
0:52
first-line camizestrant for er /her2- advanced breast cancer
-
3:30
final results from pallas: adjuvant palbociclib in hr /her2- early breast cancer
-
1:01
what emerald phase iii trial could mean for breast cancer patients | virginia kaklamani, md
-
4:14
er degrader safe, with signs of antitumour activity against er-positive breast cancer
-
7:26
s1222 hr , stage iv breast cancer: fulvestrant w/wo everolimus /- anastrozole
-
0:46
update of emerald by duration of cdk4/6i in metastatic setting: elacestrant v soc in er /her2- mbc
-
4:39
serd vs investigator’s choice of endocrine monotherapy for er /her2-advanced/mbc
-
1:39
clinical trials for stage ii-iii breast cancer
-
2:27
monarch: chemo-free options for triple-positive metastatic breast cancer
-
1:43
electra: elacestrant and abemaciclib in patients with er , her2- breast cancer
-
1:39
abemaciclib for hr /her2- advanced or metastatic breast cancer
-
1:02:48
expanding treatment options in er /her2- breast cancer: serds, serms, sercas, and more